NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

ADVANCED HEALTH INTELLIGENCE LTD (AHI)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
ADVANCED HEALTH INTELLIGENCE LTD14/12/2022
ADVANCED HUMAN IMAGING LTD11/03/202114/12/2022
MYFIZIQ LIMITED11/03/2021

Shareholder links

Our website ranking of AHI: rating 3
(3 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Group
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details

ISIN: AU0000139636
Address: Unit 5, 71-73 South Perth Esplanade South Perth, WA 6151
Tel:  08 6244 0388Fax: 08 6244 0388

Date first listed: 17/08/2015

Sector: Software & Services Industry Group: XIJ
Activities: Smartphone-based human scanning technology, with a diverse range of data-driven applications in Fitness, mHealth, Life & Health Insurance, and Apparel

News & Events

Expand this box to read and print

The securities of the company have been suspended for more than three months. If an entity does not meet the 1 or 2 year deadlines, it will be removed from the official list. The removal will usually take effect from the open of trading on the first trading day after the deadline date.

10/07/2024

The securities of the company have been suspended for more than three months. If an entity does not meet the 1 or 2 year deadlines, it will be removed from the official list. The removal will usually take effect from the open of trading on the first trading day after the deadline date.

10/07/2024

The company releases a notice of application for quotation of securities.

09/07/2024

The company releases a notice of application for quotation of securities.

09/07/2024

The company releases a notice of application for quotation of securities.

01/07/2024

The company releases a notification regarding unquoted securities.

28/06/2024

The company releases a notice of application for quotation of securities.

28/06/2024

The company releases a notification of cessation of securities.

25/06/2024

The Company has received guidelines from the Australian Securities Exchange stating that the Company's securities will be reinstated to trading on the ASX, subject to the satisfaction of certain conditions precedent. These conditions are: The Company securing AUD$4 million in cleared funds in the Company's Bank account, to the satisfaction of the ASX; and AHI will confirm the above in an ASX announcement and release any required ASX forms (including Appendix 3Bs for any proposed security issues).

19/06/2024

The company is in discussions with the Australian Securities Exchange regarding funding arrangements announced on April 15, 2024. The company plans to submit a revised funding proposal and confirm the timing of the reinstatement of its securities to trading on the ASX.

20/05/2024

The company has received a delisting notification from Nasdaq Stock Market LLC regarding its failure to meet Nasdaq Listing Rule 5550(b), which requires a minimum of US$2,500,000 in net shareholders' equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations. The company reported net shareholders' equity of AUD$2,027,882 in its Form 20-F filing with the SEC in the US for the year ended June 30, 2023, leaving a deficiency of USD$1,155,515. AHI has the right to appeal the delisting notification and will provide Nasdaq with its compliance plan and request a further extension to execute it. To address the deficiency, AHI has secured funding initiatives, including a AUD$1.957 million placement with Oakley Capital and seeking shareholder approval for a US shelf offering. The company has also prepared the necessary F-3 registration statement to seek SEC approval for the sale of securities in the US. Nasdaq's written notice does not affect the listing or trading of AHI's ADSs on Nasdaq, and the company will continue evaluating its alternatives to resolve the listing deficiency.

10/05/2024

Kalibra launches with AHI's biometrics, enabling precision health monitoring and personalised journeys. Partnership transforms health management with AI-driven biometrics, diagnostics, analytics, and machine learning. Kalibra platform tracks multiple data sources for holistic well-being and personalised actions. Collaboration empowers health professionals with real-time monitoring and data analytics for proactive care.

10/05/2024

The company releases its Commentary for the Quarter-Ended March 31, 2024 and Appendix 4C.

30/04/2024

The company lodges its Financial Statements Half Year Ended 311223.

18/04/2024

The company lodges its Appendix 4D Half-year report.

18/04/2024

The company releases a notice of proposed issue of securities.

15/04/2024

AHI has commenced a AUD$1.95 million Placement with Oakley Capital as lead manager. AHI has executed a binding terms sheet with Obsidian Global Partners to supply a further AUD$4 million in convertible notes. Up to a further USD$5 million (approx. $AUD7.6 million) is to be raised via the issue of a separate Convertible Note. AHI will seek to obtain an R&D Advance of up to AUD$1.5 million.

15/04/2024

AHI has granted an extension to Pharmak Direct's MSA, allowing additional platform integration time. AHI Technology will be embedded in the e-script process, allowing patient screening. Pharmak has a prominent stake in the e-script market throughout the MENA region. First-of-its-kind e-script and mobile screening point-of-sale offering. His Excellency Dr Obaid Al Ketbi continues to support AHI's growth throughout the region.

15/04/2024

AHI grants Changlin an extension to conclude exclusive license requirements. AHI executed a binding exclusive, perpetual license with Shanghai-based Changlin Network Technology Ltd on August 2, 2023, subject to certain conditions being met. Changlin is backed by founders with over 50 years of experience in the global health insurance sector. The license agreement includes an upfront payment of USD$10 million to AHI. AHI will receive an annual license fee of USD$5m thereafter. AHI will receive a 25% revenue share of gross sales from Changlin.

12/04/2024

There has been a delay in the lodgement of its financial report for the half-year ended 31 December 2023. The delay is to allow the Company's Auditor, PKF Brisbane Audit, time to finalise its review once the Company is able to provide further information on various potential funding solutions which the Company is considering, which is now well progressed. While the Company had anticipated that this would be finalised to allow for the release of the half-year financial report by 29 February 2024, unforeseen circumstances have caused the delay. Trading in the Company's shares is currently suspended by the ASX and will continue to be suspended until the Company can lodge its reviewed half-year financial statements with the ASX. The Company will work closely with PKF Brisbane Audit to finalise the review and expects to be able to lodge by 28 March 2024 but no later than 5 April 2024, and will work with the Auditors to shorten this time frame as far as possible.

20/03/2024

The securities of Advanced Health Intelligence Ltd were suspended at AHI's request on 5 February 2024 pending the release of an announcement in relation to various potential funding solutions referred to in its Quarterly Activities Report and Appendix 4C dated 31 January 2024. AHI's securities will now continue to be suspended from quotation under Listing Rule 17.5, due to AHI not having lodged its Half Year Report for the period ended 31 December 2023 by 29 February 2024 as required by Listing Rule 4.2. AHI's securities will remain suspended until such time that ASX is satisfied with AHI's compliance with the Listing Rules, including Listing Rule 3.1 and 4.2 and that it is otherwise appropriate for AHI's securities to be reinstated to quotation.

13/03/2024

The Company has been granted an extension to the Nasdaq shareholders' equity deficiency re-compliance period.

13/03/2024

The company releases a notice of application for quotation of securities.

08/03/2024

The Company is seeking an extension of its voluntary suspension of its securities pending the release of an announcement in relation to various potential funding solutions referred to in the Company's Quarterly Commentary and Appendix 4C, dated 31 January 2024. The Company requests that the voluntary suspension remain in place until the earlier to occur of: the Company's release of the announcement; or the commencement of trading on 7 March 2024.

01/03/2024

The company releases a notice of application for quotation of securities.

27/02/2024

The Company is seeking an extension to the voluntary suspension of its securities pending the release of an announcement in relation to various potential funding solutions referred to in the Company's Quarterly Commentary and Appendix 4C, dated 31 January 2024. The Company requests that the voluntary suspension remain in place until the earlier to occur of: the Company's release of the announcement; or the commencement of trading on 1 March 2024.

22/02/2024

The company releases a replacement Appendix 2A.

20/02/2024

The company releases a notice of cancelation of application for quotation of securities.

20/02/2024

The Company is seeking an extension to the voluntary suspension of its securities pending the release of an announcement in relation to various potential funding solutions referred to in the Company's Quarterly Commentary and Appendix 4C, dated 31 January 2024. The Company requests that the voluntary suspension remain in place until the earlier to occur of: the Company's release of the announcement referred to in paragraph 1; or the commencement of trading on 23 February 2024.

15/02/2024

The company releases a notice of application for quotation of securities.

14/02/2024

The Company requests that the voluntary suspension remain in place until the earlier to occur of: the Company's release of the announcement; or the commencement of trading on 16 February 2024.

09/02/2024

The securities of Advanced Health Intelligence Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AHI, pending the release of an announcement regarding various potential funding solutions referred to in AHI's Quarterly Commentary and Appendix 4C dated 31 January 2024.

05/02/2024

name changed from Advanced Human Imaging Ltd

14/12/2022

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    04/07/2019Peter Wall200,000$0.172$34,315
    19/06/2017Vlado Bosanac18,440$0.068$1,253
    09/06/2017Vlado Bosanac133,424$0.068$9,102
    02/03/2017Peter Wall1,000,000$0.046$45,895

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Vlado BosanacExecutive Chairman, CEO17/10/2016
    Simon DurackCFO, Company Secretary17/03/2022
    Jacqueline YeeIndependent Director20/12/2022
    Dato LowNon Exec Director13/07/2020
    Mike MelbyNon Exec Director27/10/2017
    Nick ProsserNon Exec Director18/04/2018
    Peter GoldsteinNon Exec Director29/06/2022
    Luisa IngargiolaNon Exec Director26/02/2021
    Scott MontgomeryExecutive Director, CEO01/12/2022
    Katherine IscoeExecutive Director17/08/2015

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Peter W. VaughanNon Exec Director01/12/202216/12/2022
    Edward Greissing Jr.Non Exec Director30/11/202126/05/2022
    Steven RichardsCFO02/09/201917/03/2022
    Peter WallNon Exec Chairman, CEO17/08/201522/01/2021
    Cyril DonnellyNon Exec Director17/08/201531/07/2017
    Evan CrossFinance Director17/08/201531/10/2016

    Date of first appointment, title may have changed.